“The current scenario has uncovered some structural weaknesses during the EU’s medicines offer chain plus a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides stated. She encouraged that offer chain challenges be dealt with within an EU pharmaceutical tactic predicted to be launched by the tip on the https://www.rilife.co/contact/